» Articles » PMID: 12554798

Interleukin-18

Overview
Journal J Leukoc Biol
Date 2003 Jan 30
PMID 12554798
Citations 221
Authors
Affiliations
Soon will be listed here.
Abstract

Interleukin-18 (IL-18), a recently described member of the IL-1 cytokine superfamily, is now recognized as an important regulator of innate and acquired immune responses. IL-18 is expressed at sites of chronic inflammation, in autoimmune diseases, in a variety of cancers, and in the context of numerous infectious diseases. This short review will describe the basic biology of IL-18 and thereafter address its potential effector and regulatory role in several human disease states including autoimmunity and infection. IL-18, previously known as interferon-gamma (IFN-gamma)-inducing factor, was identified as an endotoxin-induced serum factor that stimulated IFN-gamma production by murine splenocytes [(1) ]. IL-18 was cloned from a murine liver cell cDNA library generated from animals primed with heat-killed Propionibacterium acnes and subsequently challenged with lipopolysaccharide [(2) ]. Nucleotide sequencing of murine IL-18 predicted a precursor polypeptide of 192 amino acids lacking a conventional signal peptide and a mature protein of 157 amino acids. Subsequent cloning of human IL-18 cDNA revealed 65% homology with murine IL-18 [(3) ] and showed that both contain an unusual leader sequence consisting of 35 amino acids at their N terminus.

Citing Articles

The role of chemokines and interleukins in acute lymphoblastic leukemia: a systematic review.

Stajer M, Horacek J, Kupsa T, Zak P J Appl Biomed. 2025; 22(4):165-184.

PMID: 40033805 DOI: 10.32725/jab.2024.024.


Development of anti-murine IL-18 binding protein antibodies to stimulate IL-18 bioactivity.

Huard A, Fauteux-Daniel S, Goldstein J, Martin P, Jarlborg M, Andries J J Immunol. 2025; 214(1):180-191.

PMID: 40018678 PMC: 7617445. DOI: 10.1093/jimmun/vkae022.


Association of IL-18 gene polymorphisms with clinical aspects of hyperlipidemia in middle-aged and early people in the community.

Chen P, Chen W, Lien L, Chou C, Chao C, Bai C Int J Med Sci. 2024; 21(6):1064-1071.

PMID: 38774744 PMC: 11103393. DOI: 10.7150/ijms.90341.


Interleukin-12 in multimodal tumor therapies for induction of anti-tumor immunity.

Xu Y, Sun X, Tong Y Discov Oncol. 2024; 15(1):170.

PMID: 38753073 PMC: 11098992. DOI: 10.1007/s12672-024-01011-2.


Unlocking the 'ova'-coming power: immunotherapy's role in shaping the future of ovarian cancer treatment.

Haines N, Fowler M, Zeh B, Kriete C, Bai Q, Wakefield M Med Oncol. 2024; 41(3):67.

PMID: 38286890 DOI: 10.1007/s12032-023-02281-6.